News and Announcements
Second Patient In Human Cancer Trial Begins Treatment
- Published November 24, 2014 2:54PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ASX; Published: 24 November 2014
PharmAust Limited (ASX:PAA & PAA)) is pleased to report that it has initiated treatment of the second patient on 21 November 2014 in its ‘First in Man’ trial with PPL-1. To date the drug appears safe and no adverse events have been observed. The patient will receive PPL-1 daily for 28 days. The patient is suffering from lung cancer with metastases to other organs.
PharmAust’s Executive Chairmna Dr Roger Aston said “In addition to the second patient referred above, a further two patients have entered screening and, subject to their suitability, will be recruited and also begin treatment on 2 and 9 December respectively’.
Please download the document below to view the full announcement.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
